Generate a tailored SOP for Dr. Caner Saygin. Improve your application with a focused, well-structured draft.
Dr. Saygin’s laboratory investigates the biology of leukemia using in vitro and in vivo models of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as human samples from patients with malignancies. The key focus of the lab is to understand the drivers of clonal hematopoiesis indeterminate potential (CHIP) and its progression in leukemias of both myeloid and lymphoid lineages, particularly in de novo and therapy-related contexts. The overarching goal of Dr. Saygin’s translational research program is to identify the molecular and cellular mechanisms that drive these fatal diseases, and to translate insights into novel therapeutic strategies. The lab’s drug development efforts are particularly focused on high-risk subsets of AML, which have resulted in the launch of investigator-initiated phase I/II clinical trials originating directly from discoveries made in the lab.
University of Chicago • Chicago, IL
Conducts research and teaches in the field of hematology and oncology.
Department of Philosophy